Sterling Capital Management’s ADC Therapeutics ADCT Stock Holding History

Sterling Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.93K	Buy	1,802 +1,139	+172%	+$3.32K	﹤0.01%	2999
2026 Q1	$2.49K	Buy	663 +192	+41%	+$757	﹤0.01%	2944
2025 Q4	$1.66K	Buy	471 +295	+168%	+$1.2K	﹤0.01%	3088
2025 Q3	$704	Buy	176 +1	+0.6%	+$3	﹤0.01%	3128
2025 Q2	$469	Sell	175 -422	-71%	-$888	﹤0.01%	3159
2025 Q1	$842	Sell	597 -535	-47%	-$909	﹤0.01%	2868
2024 Q4	$2.25K	Buy	1,132 +1,000	+758%	+$2.62K	﹤0.01%	2755
2024 Q3	$416	Buy	+132	New	+$416	﹤0.01%	2943

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sterling Capital Management's ADCT Position: Q2 2026 in Review

Sterling Capital Management increased its ADC Therapeutics (ADCT) stake by 172% in Q2 2026, buying an estimated $3.32K and bringing the position to 1,802 shares worth $1.93K. The position accounts for ﹤0.01% of the portfolio, ranked #2999.

Sterling Capital Management first reported a position in ADCT in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.49K in Q1 2026. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

Sterling Capital Management held 1,802 shares of ADC Therapeutics worth $1.93K as of Q2 2026.
Sterling Capital Management bought 1,139 ADC Therapeutics shares in Q2 2026, an estimated $3.32K.
ADC Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2999 holding.
Sterling Capital Management first reported a position in ADC Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's ADC Therapeutics position peaked at $2.49K in Q1 2026.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.